Established in 2003, the Global HIV Vaccine Enterprise became a programme of the IAS in 2018. It works to engage stakeholders and funders to accelerate HIV vaccine development and prepare the field for the future discovery of a safe, effective and globally accessible HIV vaccine.
It does so by:
- Strengthening the HIV vaccine pipeline by encouraging diverse approaches in HIV vaccine research and advancing the HIV vaccine portfolio
- Expanding and diversifying engagement and resources by fostering interest in HIV vaccine R&D and broadening research talent within the HIV vaccine field
- Mobilizing knowledge to accelerate product development by driving opportunities to address unanswered scientific questions and leveraging synergies with other infectious disease research
Contact
[email protected]
